Roche Rebuked by U.K. on $152,850 Breast Cancer Drug
This article is for subscribers only.
The U.K.’s medical-cost oversight group rebuked Roche Holding AG today for refusing a significant price cut to a breast-cancer drug that is used only for severe cases now, but may eventually be more broadly prescribed.
The medicine, Kadcyla, costs an estimated 90,831 pounds ($152,850) for the average 14 1/2-month course of treatment, the National Institute for Health and Care Excellence said today. NICE said that’s too expensive to add the drug to the National Health Service’s budget for routine funding, even though it helped patients.